Lexicon Pharmaceuticals LXRX Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's business segments — R&D?
- Lexicon Pharmaceuticals (LXRX) reported business segments — R&D of $11.39M in Q1 2026.
- How has Lexicon Pharmaceuticals's business segments — R&D changed year-over-year?
- Lexicon Pharmaceuticals's business segments — R&D decreased by 16.3% year-over-year, from $13.61M to $11.39M.
- What is the long-term trend for Lexicon Pharmaceuticals's business segments — R&D?
- Over 3 years (2022 to 2025), Lexicon Pharmaceuticals's business segments — R&D has grown at a 4.2% compound annual growth rate (CAGR), from $48.27M to $54.59M.
- What does business segments — R&D mean?
- Expenditures dedicated to the discovery, clinical testing, and development of new products or the enhancement of existing technologies within the segment. For biopharmaceutical companies, this is a critical investment metric reflecting the pipeline's potential for future growth. High spending indicates a commitment to innovation, though it directly impacts short-term profitability.